| ||
Pharmaceutical regulatory failure must be remedied Longmont Daily Times-Call While investigations are ongoing in the fungal meningitis outbreak that has sickened more than 300 Americans and killed 24, it's clear that the regulatory system that oversees pharmaceutical compounding failed and needs to be strengthened. The steroid ... See all stories on this topic » | ||
Pharmaceutical company Boehringer Ingelheim to pay $95 million settlement Milwaukee Journal Sentinel (blog) State and federal governments will be receiving a $95 million boost from a pharmaceutical company accused of improperly marketing four drugs and paying doctors kickbacks as an incentive to prescribe the drugs. The money comes from a settlement that ... See all stories on this topic » | ||
| ||
5 Pharmaceutical Stocks to Sell Now Investorplace.com The ratings of five Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). This week, Flamel Technologies (NASDAQ:FLML) falls to a D ("sell"), worse than ... See all stories on this topic » | ||
Fla. pharmaceutical company shut down WKMG Orlando The Florida Department of Health (DOH) Friday, issued an Emergency Suspension Order (ESO) against Rejuvi Pharmaceuticals, Inc. The order shuts down the Boca Raton business from operating as a community drug compounding pharmacy in the state of ... See all stories on this topic » | ||
| ||
Watson Receives FDA Approval for Generic Actos; Forest Labs in Settlement Pact Equities.com Watson Pharmaceuticals, Inc. (NYSE: WPI) announced Watson has launched a generic version of Actos® (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets) after receiving final approval today from the U.S. FDA. Watson began shipping the product ... See all stories on this topic » | ||
CIPMMA adopts resolution opposing DCGI's order seeking to stop brand based ... pharmabiz.com The executive committee of the Consortium of Indian Pharmaceutical Manufacturers & Marketers Association (CIPMMA), an association of manufacturers of branded pharmaceutical products, has strongly condemned the DCGI's order saying that the ... See all stories on this topic » | ||
Valeant Pharmaceuticals Price Target Lowered to $67.00 at Paradigm Capital ... Zolmax Valeant Pharmaceuticals logo Valeant Pharmaceuticals (NYSE: VRX) had its price target lowered by Paradigm Capital to $67.00 in a research report sent to investors on Wednesday morning. "We continue to hold a positive view toward Valeant's unique ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment